Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers grew its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 167,560 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,755 shares during the period. Rhumbline Advisers owned about 0.28% of Jazz Pharmaceuticals worth $20,635,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. UMB Bank n.a. boosted its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. Ellsworth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after acquiring an additional 149 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,045 shares of the specialty pharmaceutical company’s stock valued at $868,000 after acquiring an additional 155 shares during the last quarter. Cooper Financial Group boosted its holdings in shares of Jazz Pharmaceuticals by 3.7% in the 4th quarter. Cooper Financial Group now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 156 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 7.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company’s stock valued at $259,000 after acquiring an additional 165 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 5,053 shares of company stock worth $617,442 over the last three months. Insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on JAZZ shares. Piper Sandler reissued an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Robert W. Baird increased their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Finally, TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $136.84 on Friday. The firm has a 50-day simple moving average of $124.59 and a 200-day simple moving average of $117.82. The stock has a market capitalization of $8.27 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 1.03 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.